Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
Bevacizumab-treated Tumor
Tissue
N/A nM (reported value)
Intracardiac injection of phage libraries. Amplified phages were partially purified by polyethyleneglycol(PEG) precipitation and resuspended in tris-buffered saline (TBS).
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Bevacizumab-Responsive Peptide (BRP) (ID# 220)
NH2LeuLeuAlaAspThrThrHisHisArgProTrpThrCOOCOOH
12
1583.81 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Cao et al. "Phage display peptide probes for imaging early response to bevacizumab treatment." Amino Acids, 41(2011): 1103-1112.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.